Foundayo (orforglipron) is Eli Lilly's first oral, small-molecule (non-peptide) GLP-1 receptor agonist FDA-approved March 2026 for chronic weight management. Q4 2026 commercial launch confirmed. Distinct from semaglutide; not interchangeable; not a generic of Ozempic/Wegovy/Rybelsus.
At a glance
- Generic name: orforglipron
- Manufacturer: Eli Lilly
- List price (cash, no coverage): TBD (Q4 2026 launch)
- Cash-pay program: Manufacturer programs expected at launch
FDA-approved indications
- Chronic weight management (March 2026 FDA approval)
- Q4 2026 commercial launch confirmed following phase 3 CV safety analysis (May 14, 2026)
Standard dosing
- Once-daily oral, non-peptide
- Dosing details disclosed at commercial launch